Glibenclamide Posttreatment Does Not Inhibit Levcromakalim Induced Headache in Healthy Participants: A Randomized Clinical Trial.

ABSTRACT: Intravenous infusion of ATP-sensitive potassium channel (K_ATP) opener levcromakalim causes headache in humans and implicates K_ATP channels in headache pathophysiology. Whether K_ATP channel blocker glibenclamide inhibits levcromakalim-induced headache has not yet been elucidated. We aimed to investigate the effect of posttreatment with glibenclamide on levcromakalim-induced headache in healthy participants. In a double blind, randomized, three-arm, placebo-controlled, crossover study, 20 healthy participants were randomized to receive 20 mL of levcromakalim (0.05 mg/min (50 mg/mL)) or 20 mL placebo (isotonic saline) intravenously over 20 min followed by oral administration of 10 mg glibenclamide or placebo. Fifteen participants completed all three study days

SUBMITTER: Kokoti L 

PROVIDER: S-EPMC10121935 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature